title: Awareness, treatment, and control of vascular risk factors in African Americans with stroke.
abstract: OBJECTIVE
  To investigate control of risk factors in African American patients with previous stroke.
  
  
  METHODS
  The baseline history, physical examination, and laboratory data for 1,086 subjects enrolled in the African American Antiplatelet Stroke Prevention Study from 1995 to 1999 were studied. The level of awareness, pharmacologic treatment, and control of diabetes mellitus (casual plasma glucose level > or =200 mg/dL), hypertension (blood pressure > or =140/90 mm Hg), and hypercholesterolemia (serum total cholesterol level > or =240 mg/dL) were determined.
  
  
  RESULTS
  Forty percent of subjects reported a history of diabetes mellitus or use of diabetic medication, and 2% of the remaining subjects had a serum glucose level of > or =200 mg/dL. Of those subjects known to be diabetic, 33% had a serum glucose level of > or =200 mg/dL. A history of hypertension or use of antihypertensive medication was reported in 87% of subjects, and 48% of the remaining subjects were found to have a blood pressure of > or =140/90 mm Hg on exam. Of those subjects known to be hypertensive by history, 73% were on antihypertensive medication, but only 30% of the treated subjects had a blood pressure under 140/90 mm Hg. A history of hypercholesterolemia or use of a lipid-lowering agent was reported in 40% of subjects, and 24% of the remaining subjects had a cholesterol level of > or =240 mg/dL. Use of a lipid-lowering agent was reported in 43% of subjects known to be hypercholesterolemic, and 38% of the hypercholesterolemic subjects had a cholesterol level of > or =240 mg/dL.
  
  
  CONCLUSIONS
  Inadequate rates of awareness and control of cardiovascular disease and stroke risk factors are seen in a clinical trial of African American stroke patients and are comparable with those of previously published reports.
authors.affiliation: Department of Neurology, Rush University, Chicago, IL 60612, USA. sruland@rush.edu
authors.forename: S
authors.initials: S
authors.lastname: Ruland
authors.forename: R
authors.initials: R
authors.lastname: Raman
authors.forename: S
authors.initials: S
authors.lastname: Chaturvedi
authors.forename: S
authors.initials: S
authors.lastname: Leurgans
authors.forename: P B
authors.initials: PB
authors.lastname: Gorelick
mesh_terms: D000328:Adult; D001741:Black or African American / Q000523:psychology / Q000706:statistics & numerical data*; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D044383:Black People; D001786:Blood Glucose; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000208:ethnology* / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000097:blood / Q000208:ethnology; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000208:ethnology; D006973:Hypertension / Q000208:ethnology; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011322:Primary Prevention / Q000193:education; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012307:Risk Factors; D020521:Stroke / Q000208:ethnology* / Q000517:prevention & control; D014481:United States
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D002784:Cholesterol